Understanding the BALANCE Model for GLP-1 Medications in Medicare and Medicaid

By
Meredith Freed
Juliette Cubanski
Elizabeth Williams
April 22, 2026
0 min

Kaiser Family Foundation (Kff)

Top Institutions in General Medicine

Brief introduction explaining scope and methodology.

#1

Joslin Diabetes Center

Boston, MA
Key Differentiators
- Endocrinology
- Diabetes Research
- Obesity Treatment
#2

Massachusetts General Hospital (MGH) Diabetes Center

Boston, MA
Key Differentiators
- Endocrinology
- Diabetes Care
- Health Policy Research
#3

University of Michigan Diabetes Research Center

Ann Arbor, MI
Key Differentiators
- Endocrinology
- Diabetes Research
- Health Policy
#4

Kaiser Permanente Division of Research

Oakland, CA
Key Differentiators
- Health Services Research
- Endocrinology
- Pharmaceutical Policy
#5

Centers for Medicare & Medicaid Services (CMS) Innovation Center

Baltimore, MD
Key Differentiators
- Health Policy
- Medicare/Medicaid Program Innovation

Original Source(s)

Kaiser Family Foundation (Kff)

Understanding the BALANCE Model for GLP-1 Medications in Medicare and Medicaid

by Meredith Freed, Juliette Cubanski, Elizabeth Williams
April 22, 2026

Related Content

Bmc Cardiovascular Disorders

Linking Stages of Cardiovascular-Kidney-Metabolic Syndrome to All-Cause Mortality Risk in U.S. Adults: Findings from a NHANES Cross-Sectional Analysis

The Medicine Maker

GLP-1 Analysis: Riding the Wave of Peptide Innovation

The remarkable commercial success of GLP-1 receptor agonists is fueling investment, accelerating science, and creating new analytical challenges. Here, we outline the hurdles these peptides present, explore methods for impurity profiling and structural characterization, and consider strategies to keep pace with this fast-moving field.